SNOG SYMPOSIUM 2024 – Multidisciplinary Neuro-Oncology Meeting

4600 kr

Artikelnr: 9771 Kategorier: ,


The meeting is now fully booked and registration is closed!



Multidisciplinary Neuro-Oncology Meeting

25th – 27th  April


Welcome to,

Scandinavian Society of Neuro-oncology (SNOG) symposium, which will be held at Clarion Hotel Draken, Olof Palmes Plats 2, Gothenburg, Sweden 25th – 27 th April 2024.

The symposium is targeted to clinical experts, clinical researchers, basic scientists and students who work with improving lives for patients with brain tumors.

Scandinavian Society of Neuro-oncology (SNOG) was established in 1980s with the overall aim to increase communication between Scandinavian neuro-oncology experts, including both basic scientists and clinicians. One important aim of SNOG is to facilitate new collaborations and improve those already established. The SNOG meeting is an excellent arena to exchange ideas, and this is the key event organized by the society.

Language: English
Number of Participants: 170
Form of Symposium: Lectures and discussion
Registration Fee: 4.600 SKR
Application deadline: April 1, 2024 Note! Limited number  of places, first came – first served!

What is included in the registration fee?

Admission to all scientific sessions
Admission to exhibition
Final Program
Coffee/tea during breaks
Lunch April 25, April 26, April 27
Dinner April 26


About hotel reservation
We highly recommend you to reserve a room at Clarion Hotel Draken, where the symposium is also held. They have reserved rooms for the participants with a special price.

More information about the hotel by this link

You can reserve your hotel room by clicking the link below:
Clarion Hotel Draken 25-27 april 2024

Special prices for participants:
Room for one person (single room) 155 EUR per night
Room for two persons (double room) 175 EUR per night
All prices are per room and per night, including breakfast buffet, Wi-Fi and VAT.

These prices are valid until February 23, 2024.

NOTE! Hotel rooms are not included in the congress fee.  The hotel rooms have to be booked and paid by each participant.

The Scandinavian Neuro-oncology Group (SNOG) encourages the submission of abstracts concerning all categories of research involving tumors involving the central nervous system (clinical, pre-clinical, translational, qualitative, register-based, etc.) but also descriptions of completed or ongoing development or quality assurance projects within the field.

Submit your abstract to SNOG by e-mail to:

The abstract submission deadline is Monday March 4, 2024.


Abstracts can be submitted in English.

Word limit
The character limit set for all abstract categories is 2 000 characters (excluding spaces). The character limit does not include the author names and affiliations or the references.

The abstract should include the following:

  • A title that reflect the content of the abstract
  • Names and affiliations of all authors, with the name of the presenting author either underlined or in bold
  • E-mail address of the presenting author
  • An introductory brief background indicating the rationale of the study
  • A brief description of methodological procedures
  • A summary of the results
  • A statement of the main conclusions
  • A brief reflection on clinical significance and future perspectives
  • References (if applicable)
  • Funding (if applicable)
  • Disclosures (if applicable)


Let us know if you primarily want:

  • Oral
  • Poster
  • No preference 

Poster presentation
Instructions for the making of posters will be sent to the presenting author in connection with a notification that the abstract has been accepted. During the meeting, a prize will be awarded to the presenter of the best poster!


We hope that this will be an interesting and productive meeting and look forward to see you in Gothenburg in April 2024.


Asgeir Jakola
President SNOG
on behalf of
SNOG Organizing committee

Members of the organising & scientific committee

Asgeir Jakola, Gothenburg, Sweden
Bjarne Winther Kristensen,  København, Denmark
Anja Smits, Gothenburg, Sweden
Maria Sandström, Umeå, Sweden
Jiri Bartek, Stockholm, Sweden
Roger Henriksson, Umeå, Sweden
Magnus Olivecrona, Örebro, Sweden
Helena Carén, Gothenburg, Sweden
Annelli Ozanne, Gothenburg, Sweden
Kirsi Rautajoki, Tampere, Finland.
Ole Solheim, Trondheim, Norway


The meeting is sponsored by


Skriv ut


April 25    
12.00 - 12.10 Welcome Asgeir Jakola, Gothenburg/Sweden
  Cognition - Chair - Anneli Ozanne  
12.10 - 12.40 Cognitive rehabilitation - lessons learned Karin Gehring, Tillburg/The Netherlands
12.40 - 12.47 Experiences of daily life challenges among patients with meningioma five years post radiotherapy: A qualitative study Linda Åkeflo, Gothenburg, Sweden
12.50 - 13.05 Cognitive trajectories in IDH mut glioma Isabelle Rydén, Gothenburg/Sweden
  Brain tumor diagnosis; beyond clinical routine - Chair - Bjarne W. Kristensen  
13.10 - 13.40 Liquid biopsies Susan Short, Leeds/UK
13.40 - 13.55 Metabolic patterns before glioma diagnosis Sebastian Löding, Umeå/Sweden
13.55 - 14.10 DNA methylation diagnostics of brain tumors now and in the future Kirsi Rautajoki, Tampere/Finland
14.10 - 14.25 PET in diagnosis of brain tumors Ian Law, Copenhagen/DK
14.25 - 14.32

Validation of a spectroscopic liquid biopsy for earlier detection of brain cancer

Holly Butler, Glasgow/UK
14.35 - 15.00 Coffee/Exhibition  
  Radiotherapy - Chair - Maria Sandström  
15.00 - 15.15 Novel PET tracers in management of brain metastasis Pirjo Laakkonen, Helsinki/Finland
15.15 - 15.30 Swedish proton experience in LGG / PRO GLIO UPDATE Malin Blomstrand, Gothenburg/Sweden

15.30 - 15.37

Prospective Phase II Trial of 68Ga-NOTA-AE105 uPAR PET/MR in Patients with Primary Gliomas: Implications for uPAR-Targeted Radionuclide Therapy

Aleena Azam, Copenhagen/Denmark

15.40 - 16.10 Experience of intraoperative radiotherapy  Klaus Henning Kahl, Augsburg/Germany
  Tumor microenvironment - Chair - Kirsi Rautajoki  
16.15 - 16.45 Tumor-host interdependance Vidhya Madapusi Ravi, Freiburg/Germany
16.45 - 17.00 Tertiary lymphoid structures; relevance in brain tumors? Anna Dimberg, Uppsala/Sweden
17.00 - 17.15 Tumor surfaceome - the key to effective immunotherapy? Mattias Belting, Lund/Sweden
17.15 - 17.30 Influence of the microenvironment on chemosensitivity in glioblastoma  Rikke Frydendahl Sick Olsen, Odense/Denmark
17.30 - 18.00 Coffee/Exhibition  
  Quality of life - Chair - Anja Smits  
18.00 - 18.15 Reproductive health and sexuality Claudia Lampic, Umeå/Sweden
18.15 - 18.30 Feasibility of shared decision making in neuro-oncology Helle Sørensen Von Essen, Odense/Denmark
18.30 - 18.45 Functional consequences of SMA and M1 resections Mattias Stålnacke, Umeå/Sweden
18.45 - 19.00 Support to patients with glioblastoma and their proxies Pernilla Ståhl, Gothenburg/Sweden
April 26
  Meningiomas - Chair - Ole Solheim  
08.30 - 08.45 Epidemiology and Incidental meningiomas Olivia Näslund, Gothenburg/Sweden
08.45 - 09.15 Molecular classification of meningiomas Felix Sahm, Heidelberg/Germany
09.15 - 09.30 Radiotherapy as primary option for meningiomas Bente Sandvei Skeie, Bergen/Norway
09.30 - 09.45 Copenhagen meningioma score Tiit Mathiesen, Copenhagen/Denmark

09.45 - 09.52

Investigating the Plasticity and Evolution of Extrachromosomal DNA in Glioblastoma Tumors at the Single-cell Level

Josephine Hendriksen, Copenhagen/ Denmark             

09.52 - 09.59

The prognostic importance of glioblastoma size and shape 

Claes Johnstad, Trondheim/Norway
10.00 - 10.07 Tracing clonal evolution in brain tumors following treatment Alessio Locallo, Copenhagen/ Denmark
10.07 - 10.14 Prognostic value of manual vs. automatic methods for assessing extents of surgical resection and residual tumour volume in glioblastoma Paulina Majewska,Trondheim/Norway 
10.15 - 10.45 Meningiomas, new horizons Thomas Graillon, Marseille/France 
11.00 - 12.00 Poster viewing - Guided - Anja Smits  

12.15 - 13.00












Lunchsymposium - Novocure

Tumor Treating Fields – experiences from an innovative treatment modality in cancer

Chair: Maria Sandström (Umeå, Sweden)
Co-Chair: Rami El Shafie (Göttingen, Germany)

Practice-changing experience of Tumor Treating Fields Therapy in newly diagnosed Glioblastoma
Speaker: Rami El Shafie

Five years of Tumor Treating Fields in the clinic - the Swedish experience 
Speaker: Maria Sandström   

Panel discussion on Tumor Treating Fields
Speakers: Maria Sandström, Rami El Shafie, Anna Rydelius (Lund, Sweden)

Symposium close 
Maria Sandström, Rami El Shafie

  Innovative study designs - Chair - Jiri Bartek  
13.00 - 13.20 Register randomized trials - what can neuro-oncology learn from the BROKEN-SWEDEHEART? Elmir Omerovic, Gothenburg/Sweden
13.20 - 13.40 Window-of-opportunity studies Michael Vogelbaum, Tampa/USA
13.40 - 14.00 Basket and umbrella trials Benedikte Hasselbalch, Copenhagen/Denmark
  Basic research topic - Chair - Helena Carén  
14.15 - 14.30 Hypoxia-driven spatial regulation in diffuse astrocytomas Aliisa Tiihonen, Tampere/Finland
14.30 - 14.45 GBM organoids, how and why Magnar Bjørås, Trondheim/Norway
14.45 - 15.00 3D chromatin organization of the glioblastoma genome Silvia Remeseiro, Umeå/Sweden
15.00 - 15.15 Novel insight into glioblastoma heterogeneity Bjarne W. Kristensen, Copenhagen/Denmark

15.15 - 15.22

PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells

Oxana Denisova, Turku & Åbo/Finland

15.25 - 15.45


Minisymposium - Cercare 
New developments in perfusion software at Karolinska University Hospital

Johan Lundberg, Stockholm/Sweden


15.45 - 16.15 Coffee/Exhibition  
  Novel therapies - Chair - Asgeir Jakola  
16.15 - 16.45 Immunotherapies including CAR-T in neuro-oncology Magnus Essand, Uppsala/Sweden
16.45 - 17.15 Neurosurgical role in oncological therapy: towards truly multidisciplinary treatment? Michael Vogelbaum, Tampa/USA
19.00 - 22.00 CONGRESS DINNER  
April 27    
  Abstract session and New concepts in IDH mutant gliomas - Chair - Asgeir Jakola  

09.00 - 09.07

Optimizing Tumor Treating Fields Therapy with skull remodeling surgery for first recurrence glioblastoma: Preliminary results from a multi-center randomized clinical trial

Anders Rosendal Korshøj, Aarhus/Denmark

09.07 - 09.14 Characteristics and Survival Rates of “Biopsy-only” Glioblastoma Patients Axel Forsse, Copenhagen/Denmark

09.14 - 09.21

Sulfasalazine as Radiosensitizer in combination with Stereotactic Radiosurgery for recurrent Glioblastoma – A phase 1 dose-escalation trial 

Bente Skeie, Bergen/Norway

09.21 - 09.28

The prognostic Value of WHO Grading for Survival Outcomes in Patients with IDH-mutant Lower Grade Glioma

Leah Lehmann, Copenhagen/Denmark

09.30 - 10.00 Vorasidenib in IDH mutated gliomas Roberta Ruda, Turin/Italy
10.00 - 10.20 Coffee/Exhibition  
  Glioma origin and growth - Chair - Bjarne W. Kristensen  
10.20 - 10.27

Violence caused by glioma patients against next of kin

Annika Malmström, Linköping/Sweden
10.27 - 10.35

Insight into spatial intratumoral genomic evolution in glioblastoma

Atul Anand, Odense/Denmark
10.35 - 10.50 Are gliomas inheritable? Adam Rosenbaum, Umeå/Sweden
10.50 - 11.05 Glioma invasion: what can we learn from current models? Sven Nelander, Uppsala/Sweden
11.05 - 11.12

Refinement of prognostication for IDH-mutant astrocytomas using DNA methylation-based classification

Sandra Vega, Gothenburg/Sweden
11.12 - 11.20

Mitochondria transfer in GBM is mediated by TGF-β and promotes increased invasiveness

Shannon Moreino, Bergen/Norway
11.20 - 11.30 Awards - best abstract/poster - Chair - Anja Smits  
  Trial updates with focus on the Nordics -  Chair - Roger Henriksson  
11.35 - 11.50 Temozolomide and Lomustine in MGMT methylated glioblastoma Annika Malmström, Linköping/Sweden
11.50 - 12.05 Optimized PCNSL treatment with BBB disruption Hanne Kuitunen, Oulo/Finland
12.05 - 12.20 Scandinavian standard of care in surgical management of LGG Margret Jensdottir, Stockholm/Sweden
12.20 - 12.35 Skull remodelling to improve TTF Anders Korshøj, Aarhus/Denmark
12.35 - 12.50 Norwegian Brain Tumor Consortium: improved access to trials Petter Brandal, Oslo/Norway
12.50 - 13.05  Tumor deliniation, novel fluorescent agents Jane S. Rasmussen, Copenhagen/Denmark
13.05 - 13.15 ADJOURN   Asgeir Jakola, Gothenburg/Sweden
  LUNCH - Restaurant Vågen 

Skriv ut